Ulrich Elben - Anavex Life Insider

Anavex Life Sciences Corp -- USA Stock  

USD 3.69  0.49  15.31%

VP of Preclinical Operations

We currently do not have informatin regarding Ulrich Elben. This executive tanure with Anavex Life Sciences Corp is not currenlty determined.
844-689-3939  http://www.anavex.com

Management Efficiency

The company has return on total asset (ROA) of (56.16) % which means that it has lost $56.16 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (95.21) % meaning that it created substantial loss on money invested by shareholders.

Entity Summary

Anavex Life Sciences Corporation, a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of Alzheimer?s disease, other central nervous system diseases, pain, and various cancers. Anavex Life Sciences Corp (AVXL) is traded on Nasdaq Capital Markets in USA. It is located in NEW YORK, U.S.A and employs 10 people. Anavex Life is listed under Business Services category by Fama And French industry classification.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Anavex Life Sciences Corp to your portfolio

Top Management

Anavex Life Sciences Leadership Team
Elliot Favus, Director, Ph.D
Athanasios Skarpelos, Director
Christopher Missling, CEO, MBA
Sandra Boenisch, Executive
Ulrich Elben, VP
M Capiak, VP
Bernd Metzner, Director, Ph.D
Steffen Thomas, Director
Peter Donhauser, Director, Ph.D

Stock Performance

Anavex Life Performance Indicators